Vaccination with Rev and Tat against AIDS.
Intro: More than 15 years after the discovery of HIV-1 as the causative agent of AIDS, and numerous attempts to develop a vaccine, it has become clear that the efficacy of the currently considered HIV-1 vaccine candidates will generally be limited. This is at least in part due to the relative resistance of so-called primary HIV strains to neutralization by HIV-1 envelope specific antibodies: even the most potent HIV-1 neutralizing antibodies failed to provide protection in in vivo models, at concentrations that can be maintained for longer periods in human vaccinees.
|Keywords||0 (Gene Products, rev), 0 (Gene Products, tat), 0 (Vaccines, Synthetic), 0 (Viral Vaccines), Acquired Immunodeficiency Syndrome/*prevention & control, Animals, Gene Products, rev/*immunology, Gene Products, tat/*immunology, Human, Macaca fascicularis, Pilot Projects, T-Lymphocytes, Cytotoxic/immunology, Vaccination, Vaccines, Synthetic/*immunology, Viral Vaccines/*immunology|
|Persistent URL||dx.doi.org/10.1016/S0264-410X(98)00498-8, hdl.handle.net/1765/3681|
Osterhaus, A.D.M.E., van Baalen, C.A., Gruters, R.A., Schutten, M., Siebelink, C.H.J., Hulskotte, E.G.J., … Sutter, G.. (1999). Vaccination with Rev and Tat against AIDS.. Vaccine, 17(20-21), 2713–2714. doi:10.1016/S0264-410X(98)00498-8